Hazem E El-Osta1, Frank E Mott2, Bryan M Burt3, Daniel Y Wang1, Anita L Sabichi1,4. 1. Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA. 2. Thoracic-Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. 3. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA. 4. Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have dramatically expanded the therapeutic landscape of non-small-cell lung cancer (NSCLC). In a previous study, gender, smoking history, and PD-L1 status were found to influence the efficacy of single-agent ICI in NSCLC. This meta-analysis evaluated the clinical and molecular factors that could predict a benefit from adding ICIs to first-line chemotherapy in metastatic NSCLC. Patients and Methods: The pooled hazard ratio (HR) of progression-free survival (PFS) and overall survival (OS) among the selected subgroups were analyzed using the random effects model. The correlation between PD-L1 expression and outcome was analyzed by meta-regression. Results: Seven phase III randomized controlled trials comparing chemo-immunotherapy (CIT) with chemotherapy in untreated stage 4 NSCLC were included. CIT evenly improved PFS irrespective of age, gender, histology, smoking history, and performance status. Among patients with baseline hepatic metastasis treated with Atezolizumab-containing CIT, PFS improvement was only detected with the addition of Bevacizumab. Whereas patients with EGFR/ALK-driven cancer exhibited greater PFS with the addition of ICI to a Bevacizumab (BEV)-based regimen, the derived benefit was no longer statistically significant among those treated with non-BEV-based regimens. Although the superior PFS conferred by CIT was noticeable across all PD-L1 expression subgroups, this benefit correlated with PD-L1 level and was more pronounced in the "PD-L1 high" cohort. Except for patients harboring EGFR/ALK aberrations or squamous histology, CIT consistently improved OS across the other selected subgroups. Conclusions: The survival advantage associated with first-line CIT in metastatic NSCLC was observed in different patient populations, including those for which single-agent ICI has marginal therapeutic benefit. Our findings support the role of chemotherapy with or without VEGF blockade as enhancers of ICI activity in NSCLC.
Background: Immune checkpoint inhibitors (ICIs) have dramatically expanded the therapeutic landscape of non-small-cell lung cancer (NSCLC). In a previous study, gender, smoking history, and PD-L1 status were found to influence the efficacy of single-agent ICI in NSCLC. This meta-analysis evaluated the clinical and molecular factors that could predict a benefit from adding ICIs to first-line chemotherapy in metastatic NSCLC. Patients and Methods: The pooled hazard ratio (HR) of progression-free survival (PFS) and overall survival (OS) among the selected subgroups were analyzed using the random effects model. The correlation between PD-L1 expression and outcome was analyzed by meta-regression. Results: Seven phase III randomized controlled trials comparing chemo-immunotherapy (CIT) with chemotherapy in untreated stage 4 NSCLC were included. CIT evenly improved PFS irrespective of age, gender, histology, smoking history, and performance status. Among patients with baseline hepatic metastasis treated with Atezolizumab-containing CIT, PFS improvement was only detected with the addition of Bevacizumab. Whereas patients with EGFR/ALK-driven cancer exhibited greater PFS with the addition of ICI to a Bevacizumab (BEV)-based regimen, the derived benefit was no longer statistically significant among those treated with non-BEV-based regimens. Although the superior PFS conferred by CIT was noticeable across all PD-L1 expression subgroups, this benefit correlated with PD-L1 level and was more pronounced in the "PD-L1 high" cohort. Except for patients harboring EGFR/ALK aberrations or squamous histology, CIT consistently improved OS across the other selected subgroups. Conclusions: The survival advantage associated with first-line CIT in metastatic NSCLC was observed in different patient populations, including those for which single-agent ICI has marginal therapeutic benefit. Our findings support the role of chemotherapy with or without VEGF blockade as enhancers of ICI activity in NSCLC.
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Martin Reck; Tony S K Mok; Makoto Nishio; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Anthony Lee; Shelley Coleman; Yu Deng; Marcin Kowanetz; Geetha Shankar; Wei Lin; Mark A Socinski Journal: Lancet Respir Med Date: 2019-03-25 Impact factor: 30.700
Authors: Paul C Tumeh; Matthew D Hellmann; Omid Hamid; Katy K Tsai; Kimberly L Loo; Matthew A Gubens; Michael Rosenblum; Christina L Harview; Janis M Taube; Nathan Handley; Neharika Khurana; Adi Nosrati; Matthew F Krummel; Andrew Tucker; Eduardo V Sosa; Phillip J Sanchez; Nooriel Banayan; Juan C Osorio; Dan L Nguyen-Kim; Jeremy Chang; I Peter Shintaku; Peter D Boasberg; Emma J Taylor; Pamela N Munster; Alain P Algazi; Bartosz Chmielowski; Reinhard Dummer; Tristan R Grogan; David Elashoff; Jimmy Hwang; Simone M Goldinger; Edward B Garon; Robert H Pierce; Adil Daud Journal: Cancer Immunol Res Date: 2017-04-14 Impact factor: 12.020
Authors: Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245
Authors: Alessio Cortellini; Biagio Ricciuti; Victor R Vaz; Davide Soldato; Joao V Alessi; Filippo G Dall'Olio; Giuseppe L Banna; Sethupathi Muthuramalingam; Samuel Chan; Margarita Majem; Aida Piedra; Giuseppe Lamberti; Elisa Andrini; Alfredo Addeo; Alex Friedlaender; Francesco Facchinetti; Teresa Gorría; Laura Mezquita; Delphine Hoton; Lacroix Valerie; Frank Aboubakar Nana; James Artingstall; Charles Comins; Massimo Di Maio; Andrea Caglio; Judith Cave; Hayley McKenzie; Thomas Newsom-Davis; Joanne S Evans; Marcello Tiseo; Antonio D'Alessio; Claudia A M Fulgenzi; Benjamin Besse; Mark M Awad; David J Pinato Journal: J Immunother Cancer Date: 2022-02 Impact factor: 13.751